The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,656 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Bioparin, LLC located in Cottonwood Heights, Utah. The grant, awarded on February 1, 2025, supports the development of biotechnological approaches to expeditiously synthesize heparin-like anticoagulants using engineered microbial cellular factories. This research aims to provide an alternative, reliable modern drug production process for unfractionated heparin (UFH) and low molecular weight heparins (LMWHs), which are critical medicines used to treat thrombosis and other clotting disorders worldwide. The project will leverage modern fermentation procedures and molecular tools to address challenges in securing a reliable heparin supply chain, which has been impacted by factors such as climate change, adulteration, and zoonotic diseases affecting animal-derived heparin sources.
Generated 3/4/25, 8:10 AM